Faheem Hasnain

Faheem Hasnain, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Gossamer Bio, Inc., Mirati Therapeutics, Inc. and Kura Oncology, Inc. Between 14 January 2022 and 2 January 2026, the trades on record add up to 15 filings.

Market trades split into 4 purchases (€1.7M) and 2 sales (€179k). Taken together, the purchases exceed the sales by €1.5M. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The rest of the record consists of 6 share grants and 2 option exercises.

A typical purchase (the median) is worth €253k. Of 4 purchases, 3 formed part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The latest filing, published on 5 January 2026, reports a share grant in Gossamer Bio, Inc. The latest purchase dates back some time: it was published 846 days ago, on 24 June 2024. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.